{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:01:05Z","timestamp":1790622065862,"version":"4.1.0"},"reference-count":48,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Dermal infiltration of eosinophils and eosinophilic spongiosis are prominent features of bullous pemphigoid lesions. Although several observations support the pathogenic role of eosinophils in bullous pemphigoid, few studies have examined the impact of skin eosinophil counts on disease severity and treatment response. This retrospective study assessed the association between eosinophil counts in skin biopsy samples of 137 patients with bullous pemphigoid and their demographic characteristics, comorbidities, disease severity, and treatment response. There was no relationship between eosinophil count and age, sex, or disease severity at disease onset. There was a positive relationship between eosinophil counts and neurological comorbidity and a negative relationship between eosinophil counts and treatment response. At all follow-up points patients with no tissue eosinophils had a better response to treatment than patients with any tissue eosinophil count. In conclusion, skin eosinophil counts in patients with bullous pemphigoid are not correlated with disease severity at onset, but can serve as a negative prognostic marker for treatment response.<\/jats:p>","DOI":"10.2340\/actadv.v102.2938","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T07:55:50Z","timestamp":1665993350000},"page":"adv00850","source":"Crossref","is-referenced-by-count":10,"title":["Skin Eosinophil Counts in Bullous Pemphigoid as a Prognostic Factor for Disease Severity and Treatment Response"],"prefix":"10.2340","volume":"103","author":[{"given":"Sharon","family":"Baum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Engler Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lyakhovitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviv","family":"Barzilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"25004","unstructured":"Baigrie D, Nookala V. Bullous pemphigoid. StatPearls. 2021 Dec 5 [cited 16 January 2022]. Available from: https:\/\/www-ncbi-nlm-nih-gov.beilinson-ez.medlcp.tau.ac.il\/books\/NBK535374."},{"key":"25005","doi-asserted-by":"crossref","unstructured":"Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26-51.","DOI":"10.1007\/s12016-017-8633-4"},{"key":"25006","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12016-017-8633-4","DOI":"10.1007\/s12016-017-8633-4"},{"key":"25007","doi-asserted-by":"crossref","unstructured":"Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol 2017; 18: 513-528.","DOI":"10.1007\/s40257-017-0264-2"},{"key":"25008","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-017-0264-2","DOI":"10.1007\/s40257-017-0264-2"},{"key":"25009","doi-asserted-by":"crossref","unstructured":"Simon D, Borradori L, Simon HU. Eosinophils as putative therapeutic targets in bullous pemphigoid. Exp Dermatol 2017; 26: 1187-1192.","DOI":"10.1111\/exd.13416"},{"key":"25010","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.13416","DOI":"10.1111\/exd.13416"},{"key":"25011","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Hammers CM, Vorobyev A, Schmidt E, Zillikens D, Ghorbanalipoor S, et al. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid. J Eur Acad Dermatol Venereol 2021; 35: 1702-1711.","DOI":"10.1111\/jdv.17303"},{"key":"25012","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17303","DOI":"10.1111\/jdv.17303"},{"key":"25013","doi-asserted-by":"crossref","unstructured":"Bernard P, Venot J, Constant F, Bonnetblane JM. Blood eosinophilia as a severity marker for bullous pemphigoid. J Am Acad Dermatol 1987; 16: 879-881.","DOI":"10.1016\/S0190-9622(87)80227-X"},{"key":"25014","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(87)80227-X","DOI":"10.1016\/S0190-9622(87)80227-X"},{"key":"25015","unstructured":"Zuo YG, Liu B, Li L, Jin HZ, Sun QN. [Correlation between blood eosinophil level and steroid doses in patients with bullous pemphigoid]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2012; 34: 130-133."},{"key":"25016","doi-asserted-by":"crossref","unstructured":"Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol 2018; 179: 1141-1147.","DOI":"10.1111\/bjd.16679"},{"key":"25017","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16679","DOI":"10.1111\/bjd.16679"},{"key":"25018","doi-asserted-by":"crossref","unstructured":"Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66: 479-485.","DOI":"10.1016\/j.jaad.2011.06.032"},{"key":"25019","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2011.06.032","DOI":"10.1016\/j.jaad.2011.06.032"},{"key":"25020","doi-asserted-by":"crossref","unstructured":"Delli FS, Sotiriou E, Lazaridou E, Apalla Z, Lallas A, Vakirlis E, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications. Dermatol Ther 2020; 33: e13958.","DOI":"10.1111\/dth.13958"},{"key":"25021","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13958","DOI":"10.1111\/dth.13958"},{"key":"25022","doi-asserted-by":"crossref","unstructured":"Giusti D, Gatouillat G, Le Jan S, Pl\u00e9e J, Bernard P, Antonicelli F, et al. Eosinophil cationic protein (ECP), a predictive marker of bullous pemphigoid severity and outcome. Sci Rep 2017; 7: 4833.","DOI":"10.1038\/s41598-017-04687-5"},{"key":"25023","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41598-017-04687-5","DOI":"10.1038\/s41598-017-04687-5"},{"key":"25024","doi-asserted-by":"crossref","unstructured":"de Graauw E, Sitaru C, Horn M, Borradori L, Yousefi S, Simon HU, et al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy 2017; 72: 1105-1113.","DOI":"10.1111\/all.13131"},{"key":"25025","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.13131","DOI":"10.1111\/all.13131"},{"key":"25026","doi-asserted-by":"crossref","unstructured":"Amber KT, Valdebran M, Kridin K, Grando SA. The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease. Front Med 2018; 5: 201.","DOI":"10.3389\/fmed.2018.00201"},{"key":"25027","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2018.00201","DOI":"10.3389\/fmed.2018.00201"},{"key":"25028","doi-asserted-by":"crossref","unstructured":"Simon D, Yousefi S, Cazzaniga S, B\u00fcrgler C, Radonjic S, Houriet C, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy 2020; 75: 669-672.","DOI":"10.1111\/all.13950"},{"key":"25029","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.13950","DOI":"10.1111\/all.13950"},{"key":"25030","doi-asserted-by":"crossref","unstructured":"Feng S, Wu Q, Jin P, Lin L, Zhou W, Sang H, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Int J Dermatol 2008; 47: 225-228.","DOI":"10.1111\/j.1365-4632.2008.03473.x"},{"key":"25031","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03473.x","DOI":"10.1111\/j.1365-4632.2008.03473.x"},{"key":"25032","doi-asserted-by":"crossref","unstructured":"Koga H, Teye K, Ishii N, Ohata C, Nakama T. High index values of enzyme-linked immunosorbent assay for bp180 at baseline predict relapse in patients with bullous pemphigoid. Front Med 2018; 5: 139.","DOI":"10.3389\/fmed.2018.00139"},{"key":"25033","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2018.00139","DOI":"10.3389\/fmed.2018.00139"},{"key":"25034","doi-asserted-by":"crossref","unstructured":"Liu Y, Wang Y, Chen X, Jin H, Li L. Factors associated with the activity and severity of bullous pemphigoid: a review. Ann Med 2020; 52: 55-62.","DOI":"10.1080\/07853890.2020.1742367"},{"key":"25035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/07853890.2020.1742367","DOI":"10.1080\/07853890.2020.1742367"},{"key":"25036","doi-asserted-by":"crossref","unstructured":"Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 2015; 172: 867-877.","DOI":"10.1111\/bjd.13717"},{"key":"25037","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13717","DOI":"10.1111\/bjd.13717"},{"key":"25038","doi-asserted-by":"crossref","unstructured":"Collins MH, Capocelli K, Yang GY. Eosinophilic gastrointestinal disorders pathology. Front Med 2018; 4: 261.","DOI":"10.3389\/fmed.2017.00261"},{"key":"25039","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2017.00261","DOI":"10.3389\/fmed.2017.00261"},{"key":"25040","doi-asserted-by":"crossref","unstructured":"Gambichler T, Segert H, H\u00f6xtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol Venereol 2015; 29: 1758-1762.","DOI":"10.1111\/jdv.12995"},{"key":"25041","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12995","DOI":"10.1111\/jdv.12995"},{"key":"25042","doi-asserted-by":"crossref","unstructured":"Gore Karaali M, Koku Aksu AE, Cin M, Leblebici C, Kara Polat A, Gurel MS. Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid. Australas J Dermatol 2021; 62: e236-e241.","DOI":"10.1111\/ajd.13547"},{"key":"25043","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ajd.13547","DOI":"10.1111\/ajd.13547"},{"key":"25044","doi-asserted-by":"crossref","unstructured":"Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol 2016; 136: 2201-2210.","DOI":"10.1016\/j.jid.2016.06.622"},{"key":"25045","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2016.06.622","DOI":"10.1016\/j.jid.2016.06.622"},{"key":"25046","doi-asserted-by":"crossref","unstructured":"Della Torre R, Combescure C, Cort\u00e9s B, Marazza G, Beltraminelli H, Naldi L, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol 2012; 167: 1111-1117.","DOI":"10.1111\/j.1365-2133.2012.11108.x"},{"key":"25047","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11108.x","DOI":"10.1111\/j.1365-2133.2012.11108.x"},{"key":"25048","doi-asserted-by":"crossref","unstructured":"Farnaghi F, Amir-Hooshang E, Kamyab-Hesary K, Abbasian S, Seirafi H, Nasimi M. Correlation of dermal and blood eosinophilia with bullous pemphigoid disease severity. Int J Womens Dermatol 2020; 6: 171-175.","DOI":"10.1016\/j.ijwd.2020.01.005"},{"key":"25049","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijwd.2020.01.005","DOI":"10.1016\/j.ijwd.2020.01.005"},{"key":"25050","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Schmidt E, Zillikens D, Ludwig RJ, Kridin K. Immunological features and factors associated with mucocutaneous bullous pemphigoid - a retrospective cohort study. J Dtsch Dermatol Ges 2021; 19: 1289-1295.","DOI":"10.1111\/ddg.14494"},{"key":"25051","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14494","DOI":"10.1111\/ddg.14494"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2938\/10450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2938\/10451","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2938\/10450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T04:14:14Z","timestamp":1673324054000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/2938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.2938","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}